Novo Nordisk has announced publication of results from the SUSTAIN 9 Phase3btrial inThe Lancet Diabetes & Endocrinology.

The objective of that 30-week trial was to assess the efficacy and safety of Ozempic(semaglutide) 1.0 mg when added to SGLT-2 inhibitor (SGLT-2i) therapy.

In SUSTAIN 9, adults with type 2 diabetes were randomised to receive once-weekly semaglutide or placebo in addition to an SGLT-2i, either as monotherapy or in combination with metformin or sulfonylurea.1

The trial met its primary endpoint, with Ozempic(semaglutide) injection 1.0 mg demonstrating a statistically significant and superior reduction in HbA1cof 1.5% vs 0.1% with placebo, both in combination with SGLT2-i treatment, from an overall mean baseline of 8.0%.Additional findings of a secondary endpoint showed that Ozempic1.0 mg demonstrated a statistically significant and superior reduction in body weight of 4.7 kg vs 0.9 kg with placebo, from an overall mean baseline of 91.7 kg.

"Despite current treatment, almost 50% of people with type 2 diabetes are still living with uncontrolled blood sugar," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "The results from SUSTAIN 9 demonstrated that Ozempic® in combination with an SGLT-2 inhibitor is effective in lowering blood sugar and reducing body weight. These data further reinforce the results from across the SUSTAIN clinical development programme and the benefits of Ozempic® that clinicians from many countries are already seeing in their day-to-day practices."

Publishing the results in The Lancet Diabetes & Endocrinology, Novo Nordisk has indicated that a trial met its primary endpoint, with Ozempic (semaglutide) injection 1.0 mg demonstrating a statistically significant and superior reduction in HbA1c.